Selskabets formål er at drive handel og fabrikation, herunder import- og eksportvirksomhed samt agentur
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 587.5 mio. | 153.6 mio. | 2.6 mia. | 2.5 mia. | 370 | |
CVR: 39582910
Secondary names: Thermo Fisher Scientific A/S, Apogent Denmark A/S, Fisher Holdings A/S
4 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 175 companies in Fremstilling af andre plastprodukter
Comparison is based on industry median values
NUNC A/S demonstrates strong financial health with a solid equity position of 2.47 billion DKK as of 2024, reflecting a significant increase from 800.62 million DKK in 2020. Revenue has stabilized around the 587 million DKK mark in 2023 and 2024, with a slight decline from 664.39 million DKK in 2022, while profit margins remain robust, hovering around 26% in recent years. The company has shown resilience in profitability, although the slight revenue decline may raise concerns about future growth. Overall, NUNC A/S holds a strong position within the plastics manufacturing industry, backed by consistent profits and a solid equity base.
AI-generated summary
Companies in the same industry and area
companydata.dk